The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.
 
Einat Shacham Shmueli
Consulting or Advisory Role - Medison; MSD
Travel, Accommodations, Expenses - Merck Serono
 
Morteza Raeisi
No Relationships to Disclose
 
Benoist Chibaudel
Honoraria - Bayer; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - BeiGene; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Merck; MSD; Roche; Sanofi
 
Timothy S. Maughan
Employment - AstraZeneca
Consulting or Advisory Role - Pierre Fabre; vertex
Research Funding - Almac Diagnostics (Inst); AstraZeneca (Inst); Merck KgAA (Inst); PsiOxus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - patent pending
 
Jean-Yves Douillard
No Relationships to Disclose
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Berlin-Chemie; Bristol-Myers Squibb; Medac; Merck KGaA; Merck Sharp Dohme; Roche; Sanofi
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; GSO; Janssen-Cilag GmbH; Merck Sharp & Dohme; Oncology Drug Consult (ODC); Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CPT Cellex Patient Treatment (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycostem (Inst); Glycotope GmbH (Inst); immatics (Inst); Incyte (Inst); IO Biotech (Inst); Ipsen (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier/Pfizer (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Merck Serono; Sanofi
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst); OBI Pharma
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Genentech/Roche
 
Richard Adams
Honoraria - Amgen; Merck Serono; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER
Speakers' Bureau - Merck Serono
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono; SERVIER
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Madrigal Pharmaceuticals; Moderna Therapeutics; Novavax; Opthea; Orphazyme; Twist Bioscience; UniQure; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax
Consulting or Advisory Role - 1Globe Health Institute; Center for Emerging & Neglected Diseases (CEND); Deciphera; FivePHusion; Genor BioPharma; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Novotech; Revolution Medicines; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Jean-Baptiste Bachet
Honoraria - Amgen; AstraZeneca; Bayer; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Sanofi; SERVIER; Viatris
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bayer; Merck Serono; Pierre Fabre; Servier
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche; Servier
 
Romain Cohen
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre
Consulting or Advisory Role - Enterome; Exeliom Biosciences
Research Funding - SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Mylan
 
Lama Sharara
No Relationships to Disclose
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pierre Fabre; Roche/Genentech; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Pierre Fabre; Seagen; Servier; SERVIER; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; Gercor
 
Qian Shi
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim; Hoosier Cancer Research Network; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Aimery De Gramont
No Relationships to Disclose